drugset / Trial / NCT02001363

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

NCT02001363

Unknown 90 enrolled Chen Wei Ren, MD
RandomizedParallel-groupDouble-blindTreatment

Summary

The investigators planned to research the cardioprotective effects of intravenous liraglutide on reperfusion injury.

Timeline

Start
2013-11
Primary completion
2016-03
Completion
2016-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous